Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of
lung tissues. REGEND001 Autologous Therapy Product, made from bronchial basal cells with
ability to regenerate lung tissue, is promising to IPF treatment. In this study, a
single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001
Autologous Therapy Product in treatment of IPF. Different doses of REGEND001 Autologous
Therapy Product is evaluated to establish a dose-response relationship and to recommend
appropriate dose for subsequent clinical trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Regend Therapeutics
Collaborators:
Peking Union Medical College Hospital Regend Therapeutics XLotus (Jiangxi) Co, Ltd. Ruijin Hospital The First Affiliated Hospital of Guangzhou Medical University